【Filgrastim zz】評論

ref: 心利正膜衣錠150毫克 RYTMONORM(Propafenone) 150MG FILM COATED TABLETS 中文仿單

【加賴叫過去】評論

抗心律不整藥物整理：

【terminator812】評論

In these patients, flecainide, propafenone, amiodarone, dronedarone, sotalol, and dofetilide are superior to placebo for maintaining sinus rhythm. (See "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials".)For those patients in whom flecainide or propafenone will not be used as the preferred agent, the following points can influence the choice of antiarrhythmic drug in patients without structural heart disease:●In the Canadian Trial of Atrial fibrillation, AFFIRM, and the SAFE-T randomized trials, amiodarone was more effective than flecainide, propafenone, or sotalol (which have nearly equivalent efficacy to each other), but has a significantly higher rate of adverse side effects. (See "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Amiodarone'.) ●In a meta-analysis of trials where the effect of amiodarone versus dronedarone was estimated with the use of indirect comparison and normal logistic meta-analysis models, amiodarone was found to be more effective in maintaining sinus rhythm, but at the expense of greater drug discontinuation secondary to adverse events [17]. (See "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Dronedarone'.) Both amiodarone and dronedarone are associated with significant side effects. We suggest carefully discussing these with the patient prior to initiating therapy. (See "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring" and "Clinical uses of dronedarone".)In the EMERALD trial, Dofetilide had a somewhat better efficacy than sotalol. (See "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Dofetilide'.)Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations - UpToDate

【Tegralition】評論

applied 11e p309, 310

【NAlexE】評論

21.下列何者不適合用於治療結構型心臟病（structural heart disease，如左心室肥大，心肌梗塞或心衰竭）病人的 心律不整？

【HUSpiTLE】評論

Class I：對有結構性心臟病或左心室功能不全的病人易造成proarrhythmia(藥物致心律不整)。尤其Class IC需避免用於心室功能不全，因會造成negative inotropic effect (負向強心)。Class II：雖不會造成proarrhythmia，但可能造成bradycardia。Class III：延長去極化作用，可能增加TdP與心室心跳過速的風險。Ref: Uptodate—Arrhythmia management for the primary care clinician